Gandhi, Ujjawal H.
Cornell, Robert F.
Lakshman, Arjun
Gahvari, Zhubin J.
McGehee, Elizabeth
Jagosky, Megan H.
Gupta, Ridhi
Varnado, William
Fiala, Mark A.
Chhabra, Saurabh
Malek, Ehsan
Mansour, Joshua
Paul, Barry
Barnstead, Alyssa
Kodali, Saranya
Neppalli, Amarendra
Liedtke, Michaela
Narayana, Swapna
Godby, Kelly N.
Kang, Yubin
Kansagra, Ankit http://orcid.org/0000-0001-6901-0782
Umyarova, Elvira
Scott, Emma C.
Hari, Parameswaran
Vij, Ravi
Usmani, Saad Z.
Callander, Natalie S.
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
Costa, Luciano J. http://orcid.org/0000-0001-5362-2469
Article History
Received: 23 December 2018
Revised: 17 February 2019
Accepted: 25 February 2019
First Online: 11 March 2019
Compliance with ethical standards
:
: EhM: Consultancy and Speakers Bureau (Takeda, Celgene, Amgen, Janssen); BP: Stock and pension plan (Bristol Myer Squibb); AN: Consultancy (Celgene, Amgen); ML: Consultancy (Amgen/Onyx), Honoraria (Amgen/Onyx, Pfizer, Prothena, Takeda), Research Funding (Amgen/Onyx, BlueBirdBio, Celgene, Genentech/Roche, Gilead, Pfizer, Prothena, Takeda), Membership on an entity’s Board of Directors or advisory committees (Caelum, Pfizer, Prothena, Takeda); PH: Consultancy and Research Funding (Amgen, Celgene), Honoraria (Celgene); RV: Honoraria (Celgene, Bristol Myers Squibb, Takeda, Amgen, Janssen, Karyopharma, Jazz), Research Funding (Celgene, Bristol Myers Squibb, Takeda); SU: Consultancy (Abbvie, Amgen, Celgene, Genmab, Merck, MundiPharma, Seattle Genetics), Research Funding (Amgen, BMS, Celgene, Janssen, Merck, Pharmacyclics, Takeda), Membership on an entity’s Board of Directors or advisory committees (Sanofi); ShK: Consultancy (AbbVie, Celgene, Janssen, Kite Pharma, Merck, Takeda); LC: Honoraria (Amgen, Celgene, AbbVie), Research Funding (Amgen, Celgene, Janssen). The remaining authors declare that they have no conflict of interest.